ⅠB2～ⅣB期晚期宫颈癌新辅助化疗后根治性手术近远期疗效分析.pdf

《ⅠB2～ⅣB期晚期宫颈癌新辅助化疗后根治性手术近远期疗效分析.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、2014年第18卷第11期实用临床医药杂志JournalofClinicalMedicineinPractice·61·IB2～ⅣB期晚期宫颈癌新辅助化疗后根治性手术近=i江远迈期疗效分析冯银珍，李红薇(解放军第422医院妇产科，广东湛江，524009)摘要：目的探讨I磁～IVB期晚期宫颈癌新辅助化疗即OXA+DT)((奥沙利铂+多西他塞)后实施根治性手术近远期疗效。方法选取本院2006年1月一2O08年12月收治的I＆～ⅣB期晚期宫颈癌患者52例为研究对象，随机将患者分为观察组及对照组，每组26例，观察组术前行0)(A+DTX联合化疗，对照患者术前行DDP+DTX化疗(顺铂+多西他

2、塞)，对比分析2组患者毒副作用、近期疗效及远期治疗效果。结果2组患者毒副反应主要表现为血液学毒反应及胃肠反应，毒副反应等级均为I～Ⅱ级，患者表现耐受，但观察组毒副反应发生率15．38％显著低于对照组69．23％，差异有统计学意义(P<0．05)。观察组近期疗效为80．77％，对照组为61．54％，2组患者近期疗效差异具有统计学意义(P<0．05)。与对照组相比，观察组术后5年生存率显著提高，而复发率显著下降，差异有统计学意义(P<0．05)。结论对I～ⅣB期晚期官颈癌患者术前行多西他赛及铂类新型辅助化疗，能有效缩小术前瘤体大小，提高患者近期及远期治疗效果。关键词：晚期官颈癌；多西他赛

3、；铂类；近远期疗效中图分类号：R737．33文献标志码：A文章编号：1672—2353(2014)11-061-03130I：10．7619~cmp．201411018ProstecdtiveefficacyandrecentefficacyofradicalsurgeryinpatientswithIB2～1VBadvancedcervicalcanceraftertreatmentofneoadjuvantchemotherapyFENGYinzhen，LIHongwei(DepartmentOfC,ynecologyandObstetrics，The422ndHospitalo

4、fPeople'sLiberationArmy，Zhanjiang，Guangdong，524009)ABSTRACT：ObjectiveToexploreprostecdtiveefficacyandrecentefficacyofradicalsurgeryinpatientswith工B2～1VBadvancedcervicalcanceraftertreatmentofneoa~uvantchemotherapy．Methods52patientswithI132～ⅣBadvancedcervicalcancerwererandomlydividedintoobserva-t

5、iongroup(=26)andcontrolgroup(72=26)．Theobservationgroupwastreatedwithdocetaxelandplatinum—basedchemotherapy，whilethecontrolgroupwastreatedwithroutinepreoperativechemotherapy．Resultsefficacyandprostecdtiveefficacywerecomparedbetweentwogroups．Re—sultsTheincidencerateofsideeffectsofobservationgrou

6、pwas15．38％，whichwassignificantlylowerthan70．73％ofcontrolgroup(P<0．05)．Comparedwiththecontrolgroup，survivalrateafter5yearsintheobservationgroupsignificantlyimproved，andtherecurrenceratesignificantlydecreased，Thereweresignificantdifferences(P<0．05)．ConclusionImplementationofpreoper-ativedocetaxel

7、andcisplatinnewadjuvantchemotherapyforpatientswith工B2～ⅣBadvancedcervi-calcancercaneffectivelyreducetumorsizeandimprovetherecentefficacyandprostecdtiveefficacy．KEYⅥ，0：advancedcervicalcancer；docetaxel；platinum；recentefficacyandprost